ONWARD MEDICAL BV EO -12 (63E) - Total Assets
Based on the latest financial reports, ONWARD MEDICAL BV EO -12 (63E) holds total assets worth €84.55 Million EUR (≈ $98.85 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ONWARD MEDICAL BV EO -12 (63E) net assets for net asset value and shareholders' equity analysis.
ONWARD MEDICAL BV EO -12 - Total Assets Trend (2021–2025)
This chart illustrates how ONWARD MEDICAL BV EO -12's total assets have evolved over time, based on quarterly financial data.
ONWARD MEDICAL BV EO -12 - Asset Composition Analysis
Current Asset Composition (December 2025)
ONWARD MEDICAL BV EO -12's total assets of €84.55 Million consist of 87.6% current assets and 12.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 80.6% |
| Accounts Receivable | €1.20 Million | 1.4% |
| Inventory | €803.00K | 1.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €7.00 Million | 8.3% |
| Goodwill | €1.74 Million | 2.1% |
Asset Composition Trend (2021–2025)
This chart illustrates how ONWARD MEDICAL BV EO -12's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ONWARD MEDICAL BV EO -12 market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ONWARD MEDICAL BV EO -12's current assets represent 87.6% of total assets in 2025, a decrease from 88.2% in 2021.
- Cash Position: Cash and equivalents constituted 80.6% of total assets in 2025, down from 85.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 8.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 8.3% of total assets.
ONWARD MEDICAL BV EO -12 Competitors by Total Assets
Key competitors of ONWARD MEDICAL BV EO -12 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.76 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
ONWARD MEDICAL BV EO -12 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.67 | 6.85 | 3.65 |
| Quick Ratio | 6.60 | 6.84 | 3.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €62.98 Million | €54.33 Million | €25.24 Million |
ONWARD MEDICAL BV EO -12 - Advanced Valuation Insights
This section examines the relationship between ONWARD MEDICAL BV EO -12's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.46 |
| Latest Market Cap to Assets Ratio | 2.27 |
| Asset Growth Rate (YoY) | 11.1% |
| Total Assets | €84.55 Million |
| Market Capitalization | $191.55 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values ONWARD MEDICAL BV EO -12's assets at a significant premium (2.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: ONWARD MEDICAL BV EO -12's assets grew by 11.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ONWARD MEDICAL BV EO -12 (2021–2025)
The table below shows the annual total assets of ONWARD MEDICAL BV EO -12 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €84.55 Million ≈ $98.85 Million |
+11.05% |
| 2024-12-31 | €76.14 Million ≈ $89.01 Million |
+74.51% |
| 2023-12-31 | €43.63 Million ≈ $51.01 Million |
-43.04% |
| 2022-12-31 | €76.59 Million ≈ $89.55 Million |
-26.91% |
| 2021-12-31 | €104.80 Million ≈ $122.52 Million |
-- |
About ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more